Navigation Links
Mymetics' HIV Vaccine Demonstrates First-Ever Production of,Neutralizing IgA Antibodies in Non-Human Primate Model

NYON, Switzerland, June 07, 2007 /PRNewswire-FirstCall/ -- Mymetics Corporation announced today analysis of results demonstrating that the Company's HIV vaccine elicited neutralizing IgA mucosal antibodies in a non-human primate model. Mucosal IgA antibodies are considered as a possible first line of defense against infection by HIV. The data were presented by Sylvain Fleury, Ph.D., Mymetics' Chief Scientific Officer, in an oral presentation titled, "Without Mucosal Adjuvant, Virosomes-gp41 Peptides from the MPR can Elicit Protective Mucosal IgA in Vaccinated Macaques," at the recent Keystone Symposium, HIV Vaccines: From Basic Research to Clinical Trials.

According to the findings, more than 90 percent of non-human primates vaccinated with virosomes expressing the HIV-1 gp41 peptide produced mucosal IgA antibodies in the genital and intestinal compartments. These mucosal antibodies were capable of preventing HIV transcytosis, a process by which HIV crosses the membrane epithelium of the mucosa, by 60 to 98 percent. When total IgA was purified for testing in standard neutralizing assays (TZMbl), the IgA antibodies also showed the ability to neutralize a primary HIV clade B virus (QH0692) known to be difficult to neutralize. Mucosal IgA produced against the HIV gp41 protein after vaccination was determined to be as good or better than the best anti-HIV neutralizing monoclonal antibodies (2F5, 4E10 and b12) currently on the market, when comparing the amount of antibodies required for neutralizing 50 percent of the viruses.

Mymetics' Dr. Fleury commented, "These results are extremely encouraging. We believe that, by using virosomes which target the mucosal compartment, we now have a means to elicit neutralizing IgA that can potentially work at low concentrations. Furthermore, virosomes do not require a mucosal adjuvant for triggering mucosal antibodies. This may cut the time to market since mucosal a
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Mymetics HIV Vaccine Achieves Research Breakthrough, Eliciting Protective Antibody Response in Mucosal Tissues of Non-Human Primate Model
2. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
3. DOR BioPharma Announces Issuance of European Patent for Its Oral Multivalent Botulinum Toxin Vaccine BT-VACC
4. From Clinical Cancer Research: Rethinking Therapeutic Cancer Vaccine Trials
5. DOR BioPharma Announces Publication Describing Results of Its Multivalent Botulinum Toxin Vaccine BT-VACC
6. Vaccine Can Prevent Cervical Cancer and Precancerous Lesions
7. Largest Cervical Cancer Vaccine Efficacy Trial Shows Cervarix Provides Excellent Protection Against Lesions Caused by Most Common Cancer-Causing Virus Types
8. Based on Up to 6 Years of Follow-Up, Biovest Announces Favorable Interim Blinded Data for Fast-Tracked Pivotal Phase 3 Clinical Trial of BiovaxID Anti-Cancer Vaccine for Non-Hodgkins Lymphoma
9. HepaLifes PBS-1 Cells for Influenza Vaccine Production Prove Superior at International Conference
10. New Flu Vaccine from PepTcell Could Provide Immunity Against All Strains of Influenza Virus
11. Hypertension Vaccine CYT006-AngQb Achieves Strong Blood Pressure Reduction During Important Early Morning Period When Most Adverse Cardiovascular Events Occur
Post Your Comments:
(Date:3/27/2015)...  Valeant Pharmaceuticals International, Inc. (NYSE: VRX ) ... announced registered offering of common shares in ... the Offering, the Company issued 7,286,432 common shares at ... proceeds of approximately $1.45 billion. On March 18, 2015, ... Commission a final prospectus supplement to its effective shelf ...
(Date:3/27/2015)... , March 27, 2015 As ... shipments of incontinence devices for women. ... the most gratifying part is the hundreds of ... women whose lives have been positively impacted by ... of InControl. InControl recently released Apex, ...
(Date:3/27/2015)... 2015   Hospira, Inc. (NYSE: ... the world,s leading provider of injectable drugs and ... evaluation of biosimilarity of its proposed biosimilar, Epoetin ... (FDA) conditionally approved name of RETACRIT™, compared to ... study data were presented at the National Kidney ...
Breaking Medicine Technology:Valeant Pharmaceuticals Closes Offering Of $1.45 Billion Of Common Shares 2Valeant Pharmaceuticals Closes Offering Of $1.45 Billion Of Common Shares 3InControl Medical Surpasses 40,000 Shipments Of Incontinence Devices For Women 2Hospira Clinical Data Shows Proposed Biosimilar, Epoetin Hospira, Demonstrates Pharmacokinetic And Pharmacodynamic Equivalence Compared To Amgen's Epogen 2Hospira Clinical Data Shows Proposed Biosimilar, Epoetin Hospira, Demonstrates Pharmacokinetic And Pharmacodynamic Equivalence Compared To Amgen's Epogen 3
... Primary Endpoint of the Trial to Be Clarified ... Arbios Systems, Inc.,(OTC Bulletin Board: ABOS) announced today ... U.S. Food and Drug Administration ("FDA") of,an Investigational ... for SEPET(TM), Arbios, extracorporeal (outside the body) artificial,liver ...
... Feb. 21 Accumetrics, Inc. a privately-held,medical device ... tests that,measure patient response to antiplatelet drugs, announced ... Series D financing. The syndicate was led by,Arnerich ... Also participating,in the round were previous investors: Essex ...
Cached Medicine Technology:Arbios Receives Conditional Approval from the FDA to Initiate Pivotal Clinical Trial for SEPET(TM) 2Arbios Receives Conditional Approval from the FDA to Initiate Pivotal Clinical Trial for SEPET(TM) 3Arbios Receives Conditional Approval from the FDA to Initiate Pivotal Clinical Trial for SEPET(TM) 4Accumetrics Announces $28.8 Million Financing and Initiation of Pivotal Clinical Trial 2
(Date:3/28/2015)... March 28, 2015 "Necrorun" was featured ... takes a look at the latest and coolest applications ... Troohey, the host of NewsWatch and technology expert, conducted ... is an entertaining endless runner game with knights, nature, ... was released in 2009, according to Eurogamer. The popularity ...
(Date:3/28/2015)... (PRWEB) March 28, 2015 With ... in the fields of osteoporosis, osteoarthritis and musculoskeletal ... Osteoporosis, it may be the first time in ... research forum that the hot-button topic is an ... on the well-accepted scientific principles of Wolff’s law, ...
(Date:3/28/2015)... March 28, 2015 The California-based leading ... for every customer shopping on UniWigs during the Easter ... be a big promotion on April Fools’ Day. , ... is just around the corner. Easter Festival, with religious ... is a major holiday after Christmas. The best wig ...
(Date:3/28/2015)... FL (PRWEB) March 28, 2015 ... conditions coverage is made available to all visitors who ... effective immediately. All members are encouraged to purchase the ... to avoid lack of proper coverage for pre-existing medical ... from one or two medical conditions with serious consequences ...
(Date:3/28/2015)... 28, 2015 Centurion Service Group will be ... Thursday, April 2 at their Las Vegas warehouse, located at ... The sale, which consists of equipment from hospitals and surgery ... 9 a.m. PDT. , Buyers will find items of ... “We are a one-stop-shop,” said Erik Tivin, CEO of Centurion. ...
Breaking Medicine News(10 mins):Health News:A Grim Endless Runner Game Was Featured on NewsWatch Television on January 30, 2015 2Health News:Non-Drug Protocol for Building Bone Density Expected to Steal Spotlight at World Congress on Osteoporosis 2Health News:UniWigs Is Sending Out Mysterious Gifts During the Easter Holidays 2Health News:India Network Health Insurance Today Announces New Eligibility Criteria for Pre-existing Condition Health Insurance Coverage for Visitors to the United States 2Health News:India Network Health Insurance Today Announces New Eligibility Criteria for Pre-existing Condition Health Insurance Coverage for Visitors to the United States 3Health News:Medical Equipment Auction to Take Place in North Las Vegas 2
... no proof the procedures work and serious side effects ... News) -- Claims by spas that "lipodissolve" injections can ... also remains in question, according to warning letters issued ... The FDA warned six U.S. based medical spas and ...
... iron to Alzheimer,s disease, heart disease, and other age-related disorders, ... suggests specific steps that older consumers can take to ... their bodies. "This story of copper and iron toxicity, which ... is virtually unknown to the general medical community, to say ...
... ... announced today that it has appointed Mick Simon to serve as Executive Vice President ... Business Intelligence Solutions and personal health management clinical services to self insured employers, other ... , ...
... Adherence to treatment declines if adults fail to monitor, ... Children and teens with type 1 diabetes are less ... parents become lax about monitoring their treatment or if ... found. , Failure to properly manage type 1 diabetes, ...
... hooking up takes over from dating as a means of ... to prefer dating whereas more men than women rate hooking ... risks to dating and hooking up. Carolyn Bradshaw from James ... that motivate college men and women to hook up or ...
... this as troubling individually and for society , WEDNESDAY, ... mobility are increasing among middle-age Americans, a new study ... long-term consequences for the U.S. health-care system. , Researchers ... data from the annual National Health Interview Survey, covering ...
Cached Medicine News:Health News:FDA Issues Warning on 'Fat-Melting' Spa Injections 2Health News:HCMS Group LLC Names Mick Simon Chief Operating Officer 2Health News:Kids Need Parents' Help in Managing Type 1 Diabetes 2Health News:Hooking up or dating: Who benefits? 2Health News:Middle-Age Americans Less Mobile Than Ever 2
Silicone Foley Catheters 2-Way (Pediatric)...
Midstream Catch Kits...
Midstream Catch Kits...
... The Pediatric BladderScan® is ... Diagnostic Ultrasound's trusted family ... enabling healthcare providers to ... volume noninvasively, this easy-to-use, ...
Medicine Products: